Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2004

View Archived Issues

Wyeth to manufacture Herceptin for Genentech

Preliminary results from phase II study of Furosemide GR

Nastech and Merck & Co form alliance over PYY3-36 Nasal Spray

Two series of anti-HIV CCR5 antagonists reported by Takeda

Kissei scientists prepare ZAP-70 and Syk kinase inhibitors for use in immune disorders

New MCH-1R antagonists and their use in obesity, diabetes, etc.

BCRP inhibitors and their use as drug resistance modulators described by Yakult Honsha

Novel muscarinic M4 agonists with potential in schizophrenia therapy

Ono presents new prostanoid EP3 antagonists and their use in pain and other disorders

Teijin patent covers new vitamin D analogues for bone disorders

Novel antibacterial carbapenems prepared and evaluated by Meiji Seika team

Discovery of inhibitors of the MDM-p53 protein-protein interaction

Apoptosis inducer shows promise in phase I trial in cancer patients

In vitro and in vivo activity of small-molecule HDAC inhibitor

Orphan drug designation gives Gliadel exclusivity to 2010

Desilux enters phase III program for atopic dermatitis

Pharmacopeia delivers leads in Neurocrine collaboration

Palladone extended-release capsules approved for persistent pain

Statins show antiproliferative effects on pancreatic adenocarcinoma

CombinatoRx and ABC2 establish brain cancer collaboration

Preliminary data reported from phase I trial of antiangiogenic peptide

BioMedicines changes name to Intarcia Therapeutics

Schwarz launches Parcopa

IL-2 does not influence pharmacokinetics of CNTO-328 in monkeys

Preliminary data support the use of AGI-1067 in coronary atherosclerosis

European approval for Raptiva for psoriasis

Full enrollment reached in phase II trial of CYT002-NicQb

European CHMP gives positive opinion for extension of indication for Pegasys

Extension of indication recommended for Taxotere in E.U.

New targeted delivery methodology for male contraception

mGlu4 receptor modulator has anxiolytic-like effects

Visilizumab mechanism, clinical benefit investigated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...